| Mark R Thiele, MD | |
|
595 W Lake Mead Pkwy, Henderson, NV 89015-7015 | |
| (702) 565-1007 | |
| (702) 565-0836 |
| Full Name | Mark R Thiele |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 19 Years |
| Location | 595 W Lake Mead Pkwy, Henderson, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467593715 | NPI | - | NPPES |
| 001662200 | Medicaid | FL | |
| 20364 | Other | NV | STATE LICENSE |
| 1467593715 | Medicaid | NV |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | ME104257 (Florida) | Secondary |
| 207Q00000X | Family Medicine | 20364 (Nevada) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Medical Holdings Nevada Inc | 7416054622 | 286 |
News Archive
John DeLuca, PhD, senior vice president for Research and Training at Kessler Foundation, has received a $95,000 sub-award from EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada.
The former British Prime Minister Tony Blair will today open the "What Makes a Champion?" forum in Beijing in the lead-up to the opening of the Olympic Games on Saturday. Prime Minister Kevin Rudd will deliver a video message.
New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1
Current guidelines recommend stopping cervical cancer screening at age 65, but women over age 65 make up over one in five new cervical cancer diagnoses, and are twice as likely to die after a cervical cancer diagnosis compared to younger women.
› Verified 2 days ago
| Entity Name | Healthcare Partners Medical Group Coats Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487631917 PECOS PAC ID: 5991866303 Enrollment ID: O20100113000898 |
News Archive
John DeLuca, PhD, senior vice president for Research and Training at Kessler Foundation, has received a $95,000 sub-award from EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada.
The former British Prime Minister Tony Blair will today open the "What Makes a Champion?" forum in Beijing in the lead-up to the opening of the Olympic Games on Saturday. Prime Minister Kevin Rudd will deliver a video message.
New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1
Current guidelines recommend stopping cervical cancer screening at age 65, but women over age 65 make up over one in five new cervical cancer diagnoses, and are twice as likely to die after a cervical cancer diagnosis compared to younger women.
› Verified 2 days ago
| Entity Name | Intermountain Medical Holdings Nevada Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245997279 PECOS PAC ID: 7416054622 Enrollment ID: O20220214001765 |
News Archive
John DeLuca, PhD, senior vice president for Research and Training at Kessler Foundation, has received a $95,000 sub-award from EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada.
The former British Prime Minister Tony Blair will today open the "What Makes a Champion?" forum in Beijing in the lead-up to the opening of the Olympic Games on Saturday. Prime Minister Kevin Rudd will deliver a video message.
New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1
Current guidelines recommend stopping cervical cancer screening at age 65, but women over age 65 make up over one in five new cervical cancer diagnoses, and are twice as likely to die after a cervical cancer diagnosis compared to younger women.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark R Thiele, MD 6355 S Buffalo Dr Fl 3, Las Vegas, NV 89113-2133 Ph: (702) 216-3346 | Mark R Thiele, MD 595 W Lake Mead Pkwy, Henderson, NV 89015-7015 Ph: (702) 565-1007 |
News Archive
John DeLuca, PhD, senior vice president for Research and Training at Kessler Foundation, has received a $95,000 sub-award from EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada.
The former British Prime Minister Tony Blair will today open the "What Makes a Champion?" forum in Beijing in the lead-up to the opening of the Olympic Games on Saturday. Prime Minister Kevin Rudd will deliver a video message.
New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1
Current guidelines recommend stopping cervical cancer screening at age 65, but women over age 65 make up over one in five new cervical cancer diagnoses, and are twice as likely to die after a cervical cancer diagnosis compared to younger women.
› Verified 2 days ago
Mrs. Raegan Mccorkle, FNP Family Medicine Medicare: Medicare Enrolled Practice Location: 3248 Timorasso Ave, Henderson, NV 89044 Phone: 219-902-8309 | |
David Tit-chiu Chan, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 106 E Lake Mead Pkwy, #107, Henderson, NV 89015 Phone: 702-616-4870 | |
Mr. Bikramjit Singh Nanar, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1382 Opal Valley St, Henderson, NV 89052 Phone: 416-318-8106 Fax: 905-405-8972 | |
David S Gothelf, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 N Green Valley Pkwy, Suite 210, Henderson, NV 89074 Phone: 702-269-9995 Fax: 702-944-4056 | |
Nancy C. Chu, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2789 Sunridge Heights Pkwy, Suite 100, Henderson, NV 89052 Phone: 702-614-0850 Fax: 702-614-0987 | |
Nauhar Bhatia, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10624 S Eastern Ave Ste A-955, Henderson, NV 89052 Phone: 702-800-5393 Fax: 702-407-7016 | |
Dr. Nima Allen Alinejad, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2200 Paseo Verde Pkwy Ste 190, Henderson, NV 89052 Phone: 702-589-4871 |